Immunogenicity and Safety of COVID-19 Vaccines in Patients with Lung Cancer: Results of a Systematic Review and Meta-Analysis.

IF 2.5 4区 医学 Q3 ALLERGY
Zhizhao Zhang, Yahui Wang, Jing Zhao, Lei Liu, Pancen Ran, Yang Shu, Wei Xu, Guobin Fu
{"title":"Immunogenicity and Safety of COVID-19 Vaccines in Patients with Lung Cancer: Results of a Systematic Review and Meta-Analysis.","authors":"Zhizhao Zhang, Yahui Wang, Jing Zhao, Lei Liu, Pancen Ran, Yang Shu, Wei Xu, Guobin Fu","doi":"10.1159/000542281","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>COVID-19 has emerged as a significant worldwide health crisis in recent years, characterized by elevated morbidity and mortality rates. COVID-19 vaccinations can diminish transmission and safeguard people. The evaluation of immunogenicity and safety in high-risk populations, such as lung cancer patients, continues to provide a problem. This evaluation seeks to evaluate the safety and immunogenicity of COVID-19 vaccinations in patients with lung cancer.</p><p><strong>Methods: </strong>A search was conducted in PubMed, EMBASE, and Web of Science from January 2021 to November 2022 utilizing the keywords: COVID-19 OR SARS-CoV-2 AND COVID-19 vaccination AND lung cancer OR lung carcinoma. The subsequent requirements must be satisfied for inclusion: (1) research involving at least 30 lung cancer patients undergoing active antitumor therapy alongside healthy controls; (2) COVID-19 vaccination; (3) observational studies (either prospective or retrospective) and clinical trials featuring healthy controls; (4) the primary outcome measured was anti-SARS-CoV-2-spike IgG titers following the second dose of the COVID-19 vaccine in lung cancer patients. Secondary results included local and systemic adverse responses following the first and second doses. Antibody titers (mean ± standard deviation) were assessed for each study individually. The occurrence of adverse events following the first and second dosages was recorded.</p><p><strong>Results: </strong>Eight studies were included, comprising 1,220 lung cancer patients and 599 healthy persons. IgG titers against the SARS-CoV-2-spike protein were markedly reduced in lung cancer patients compared to healthy controls, with a statistically significant difference (p = 0.002). The safety profiles of lung cancer patients and healthy individuals were comparable: local reaction after the first vaccine: relative risk (RR) = 0.90, 95% CI: 0.68-1.19; systemic reaction after the first vaccine: RR = 0.92, 95% CI: 0.51-1.66; local reaction after the second vaccine: RR = 0.81, 95% CI: 0.54-1.19; systemic reaction after the second vaccine: RR = 1.20, 95% CI: 0.65-2.21.</p><p><strong>Conclusion: </strong>The antibody titer in lung cancer patients is markedly lower than that in the healthy group. Consequently, fatalities from COVID-19 may transpire in these people notwithstanding vaccination. Consequently, comprehensive protective measures must continue to be implemented to safeguard lung cancer patients who have received two doses of the COVID-19 vaccination against COVID-19.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-12"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Allergy and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542281","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: COVID-19 has emerged as a significant worldwide health crisis in recent years, characterized by elevated morbidity and mortality rates. COVID-19 vaccinations can diminish transmission and safeguard people. The evaluation of immunogenicity and safety in high-risk populations, such as lung cancer patients, continues to provide a problem. This evaluation seeks to evaluate the safety and immunogenicity of COVID-19 vaccinations in patients with lung cancer.

Methods: A search was conducted in PubMed, EMBASE, and Web of Science from January 2021 to November 2022 utilizing the keywords: COVID-19 OR SARS-CoV-2 AND COVID-19 vaccination AND lung cancer OR lung carcinoma. The subsequent requirements must be satisfied for inclusion: (1) research involving at least 30 lung cancer patients undergoing active antitumor therapy alongside healthy controls; (2) COVID-19 vaccination; (3) observational studies (either prospective or retrospective) and clinical trials featuring healthy controls; (4) the primary outcome measured was anti-SARS-CoV-2-spike IgG titers following the second dose of the COVID-19 vaccine in lung cancer patients. Secondary results included local and systemic adverse responses following the first and second doses. Antibody titers (mean ± standard deviation) were assessed for each study individually. The occurrence of adverse events following the first and second dosages was recorded.

Results: Eight studies were included, comprising 1,220 lung cancer patients and 599 healthy persons. IgG titers against the SARS-CoV-2-spike protein were markedly reduced in lung cancer patients compared to healthy controls, with a statistically significant difference (p = 0.002). The safety profiles of lung cancer patients and healthy individuals were comparable: local reaction after the first vaccine: relative risk (RR) = 0.90, 95% CI: 0.68-1.19; systemic reaction after the first vaccine: RR = 0.92, 95% CI: 0.51-1.66; local reaction after the second vaccine: RR = 0.81, 95% CI: 0.54-1.19; systemic reaction after the second vaccine: RR = 1.20, 95% CI: 0.65-2.21.

Conclusion: The antibody titer in lung cancer patients is markedly lower than that in the healthy group. Consequently, fatalities from COVID-19 may transpire in these people notwithstanding vaccination. Consequently, comprehensive protective measures must continue to be implemented to safeguard lung cancer patients who have received two doses of the COVID-19 vaccination against COVID-19.

COVID-19疫苗在肺癌患者中的免疫原性和安全性:系统回顾和荟萃分析结果。
导言:近年来,COVID-19 已成为全球范围内的重大健康危机,其特点是发病率和死亡率均有所上升。接种 COVID-19 疫苗可以减少传播并保护人们的健康。对肺癌患者等高危人群的免疫原性和安全性进行评估仍然是一个难题。本评估旨在评价肺癌患者接种 COVID-19 疫苗的安全性和免疫原性:在 2021 年 1 月至 2022 年 11 月期间,利用关键字在 PubMed、EMBASE 和 Web of Science 中进行了搜索:COVID-19 OR SARS-CoV-2 AND COVID-19 vaccination AND lung cancer OR lung carcinoma。纳入研究必须满足以下要求:(1) 研究涉及至少 30 名正在接受积极抗肿瘤治疗的肺癌患者和健康对照组;(2) COVID-19 疫苗接种;(3) 观察性研究(前瞻性或回顾性)和以健康对照组为对象的临床试验;(4) 主要测量结果为肺癌患者接种第二剂 COVID-19 疫苗后的抗 SARS-CoV-2 穗状病毒 IgG 滴度。次要结果包括第一剂和第二剂后的局部和全身不良反应。抗体滴度(平均值±标准偏差)按每项研究单独评估。结果:共纳入 8 项研究,包括 1,220 名肺癌患者和 599 名健康人。与健康对照组相比,肺癌患者抗 SARS-CoV-2 棘突蛋白的 IgG 滴度明显降低,差异有统计学意义(P=0.002)。肺癌患者和健康人的安全性相当:首次接种后出现局部反应:RR=0.90,95% CI:0.68-1.19;首次接种后出现全身反应:RR=0.92,95% CI:0.51-1.66;第二次接种后出现局部反应:RR=0.81,95% CI:0.54-1.19;第二次接种后的全身反应:RR=1.20,95% CI:0.65-2.21:肺癌患者的抗体滴度明显低于健康人群。结论:肺癌患者的抗体滴度明显低于健康人群,因此,尽管接种了 COVID-19 疫苗,这些人仍有可能死于该疫苗。因此,必须继续实施全面的保护措施,以保护已接种两剂 COVID-19 疫苗的肺癌患者免受 COVID-19 的感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.60%
发文量
105
审稿时长
2 months
期刊介绍: ''International Archives of Allergy and Immunology'' provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信